Using my important indicators, I know how the market is behaving.
Good news out for AEZS. Price target $10 this month, $20 end of year.
Looking for a potential run-up heading into the PDUFA announcement on 30-Dec. Reasoning: Ex-CEO David Dodd left the company just before a lawsuit was launched against him for trying to obtain personal rights for the lead drug candidate Macrilen. For him to act in such a way, its quite possible that he see good future potential for the product. Buy zone: $1.60 -...
Broke above resistance with vol. Upward trend confirmed. RSI upturn and vortex indicator cross signalling breakout
Buy AEZS on pullback to support 1st target 5
Short Sell AEZS, many people have pumped and dumped already.
AEZS up on volume. Intra-day charts confirm breakout and price closed near HOD. Breakout continued after news of licensing deal announced 12/1/2014. Price target is gap on 11/5. If you like this idea, check out my blog at thebreakouttrader.com where I post a weekly watch list of potential breakouts, good trade/bad trade article and more.
We have been monitoring $AEZS for sometime. The stock has crossed key technical indicators. We are bullish. We are are confident the stock will remain relatively stable now that the base of support is forming above the 200EMA. We will also look to buy the stock on weakness. Given that this is a BIOTECH that is dependant on clinical trials and FDA approval,...